Aldevron Partners with Acuitas Therapeutics to Boost mRNA LNP Capabilities

• Aldevron, a global manufacturer of DNA, RNA, and proteins, has entered a strategic partnership with Acuitas Therapeutics, a biotechnology company specializing in nucleic acid therapeutics.

• The partnership will allow Aldevron to expand its capabilities in mRNA LNP encapsulation by incorporating Acuitas’ proprietary LNP encapsulation platform.

Aldevron, a global manufacturer of DNA, RNA, and proteins, has announced a strategic partnership with Acuitas Therapeutics, a private biotechnology company that specialises in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).

The collaboration will enable Aldevron to expand its capabilities in mRNA LNP encapsulation. This is achieved by incorporating Acuitas’ proprietary LNP encapsulation platform, thereby increasing Aldevron’s services and capabilities as an mRNA sequence-to-vial custom manufacturer.

In the previous year, Aldevron had expanded its mRNA production capabilities to include Cytiva’s mRNA LNP encapsulation and aseptic fill-finish platform. The new strategic partnership with Acuitas Therapeutics equips Aldevron with a diverse range of mRNA LNP technologies, significantly enhancing its mRNA end-to-end drug product service capabilities.

Mark Wetzel, Vice President mRNA CDMO at Aldevron, said, “This collaboration with Acuitas is an exciting addition to our existing mRNA sequence-to-vial services and will enable Acuitas partners to leverage Aldevron’s extensive mRNA manufacturing experience and comprehensive end-to-end capabilities.”

Chris Barbosa, Vice President of Technology Development at Acuitas Therapeutics, expressed his pleasure at working with Aldevron. He said, “We look forward to Aldevron’s contribution to working with us to support our global partners in bringing new mRNA-based therapies to patients as quickly and efficiently as possible.”